Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)

Vaccine

Volumn 28, Issue 49, 2010, Pages 7748-7756

  Fellows, Patricia ^a   Adamovicz, Jeffrey ^b,c   Hartings, Justin ^d   Sherwood, Robert ^e   Mega, William ^e   Brasel, Trevor ^e   Barr, Ed ^e   Holland, Lou ^f   Lin, Winston ^f   Rom, Amanda ^f   Blackwelder, William ^g   Price, Jessica ^a   Morris, Stephen ^a,h   Snow, Doris ^a   Hart, Mary Kate ^a  

^a A CSC Company   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c MIDWEST RESEARCH INSTITUTE   (United States)

^d 539 Metropolitan Court   (United States)

^e LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^f IIT RESEARCH INSTITUTE   (United States)

^g Biologics Consulting Group   (United States)

^h U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Passive transfer; Pneumonic plague; RF1V vaccine; Yersinia pestis

Indexed keywords

ANTIBODY; PLAGUE VACCINE;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; HUMAN; HUMORAL IMMUNITY; MACACA; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PLAGUE; PRIORITY JOURNAL; SURVIVAL TIME; YERSINIA PESTIS;

ANIMALS; ANTIBODIES, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION, PASSIVE; MACACA FASCICULARIS; MICE; PLAGUE; PLAGUE VACCINE; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; YERSINIA PESTIS;

EID: 78349312669     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.062     Document Type: Article

References (40)

1. Perry R.D., Featherston J.D. Yersinia pestis - etiological agent of plague. Clin Microbiol Rev 1997, 10:35-66.
2. Gage K.L., Dennis D.T., Tsai T.F. Prevention of plague: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996, 45(RR-14):1-15.
3. Stenseth N.C., Atshabar B.B., Begon M., Belmain S.R., Bertherat E., Carniel E., et al. Plague: past, present, and future. PLoS Med 2008, 5(1):9-13.
4. Inglesby T.V., Dennis D.T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., et al. Plague as a biological weapon, medical and public health management. JAMA 2000, 283(17):2286-2290.
5. Cavanaugh D.C., Elisberg B.L., Llewelly C.H., Marshall J.D., Rust J.H., Williams J.E., et al. Plague immunization: V. Indirect evidence for the efficacy of plague vaccine. J Infect Dis 1974, 129:S37-S40.
6. Williamson E.D., Eley S.M., Griffin K.F., Green M., Russell P., Leary S.E.C., et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microb 1995, 12:223-230.
7. Williamson E.D., Stagg A.J., Eley S.M., Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 1997, 15:1079-1084.
8. Anderson G.W., Heath D.G., Bolt C.R., Welkos S.L., Friedlander A.M. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am J Trop Med Hyg 1998, 58(6):793-799.
9. Heath D.G., Anderson G.W., Maruo J.M., Welkos S.L., Andrews G.P., Adamovicz J. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998, 16(11/112):1131-1137.
10. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russel P., Titball R.W. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 2001, 19:566-571.
11. Meyer K.F. Effectiveness of live or killed plague vaccines in man. Bull World Health Organ 1970, 42:653-666.
12. Meyer K.F., Cavanaugh D.C., Batrtelloni P.J., Marshall J.D. Plague immunization: I. Past and present trends. J Infect Dis 1974, 129(Suppl.):S13-S18.
13. Marshal J.D., Batrtelloni P.J., Cavanaugh D.C., Kadull P.J., Meyer K.F. Plague immunization. II. Relation of adverse clinical reactions to multiple immunization with killed vaccine. J Infect Dis 1974, 129(Suppl.):S19-S25.
14. Feodorova V.A., Corbel M.J. Prospects for new plague vaccines. Expert Rev Vaccines 2009, 8(12):1721-1738.
15. Yamanaka H., Hoyt T., Yang X., Bowen R., Golden S., Crist K., et al. A parenteral DNA vaccine protects against pneumonic plague. Vaccine 2010, 28(10):3219-3230.
16. Brewoo J.N., Powell T.D., Stinchcomb D.T., Osorio J.E. Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice. Vaccine 2010, 28(36):5891-5899.
17. Boyer J.L., Sofer-Podesta C., Ang J., Hackett N.R., Chiuchiolo M.J., Senina S., et al. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsid antigen incorporated into adenovirus capsid. Hum Gene Ther 2010, 21(7):891-901.
18. Jones A., Bosio C., Goodyear A., Schriefer M., Dow S. Protection against pneumonic plague following oral administration with a non-replicating vaccine. Vaccine 2010, 28(36):5924-5929.
19. Eyles J.E., Williamson E.D., Spier I.D., Alpar H.O. Generation of protective immune response to plague by muscosal administration of microsphere coencapsulated recombinant subunits. J Control Release 2000, 63:191-200.
20. Williamson E.D., Flick-Smith H.C., LeButt C., Rowland C.A., Jones S.M., Waters E.L., et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 2005, 73(6):3598-3608.
21. Pitt ML. Non-human primates as a model for pneumonic plague. In: Animal models and correlates of protection for plague vaccines workshop. Gaithersburg, MD; October 13-14, 2004. http://www.fda.gov/cber/minutes/plague101304t.pdf.
22. Morris S.R. Development of a recombinant vaccine against aerosolized plague. Vaccine 2007, 25(16):3115-3117.
23. Smiley S.T. Current challenges in the development of vaccines for pneumonic plague. Expert Rev 2008, 7(2):209-221.
24. Smiley S.T. Immune defense against pneumonic plague. Immunol Rev 2008, 225:256-271.
25. Jawetz E., Meyer K.F. Studies on plague immunity in experimental animals. J Immunol 1943, 1-14.
26. Meyer K.F., Foster L.E. Measurement of protective serum antibodies in human volunteers inoculated with plague prophylactics. Stanford Med Bull 1948, 6:75-79.
27. Motin V.L., Nakajima R., Smirnov G.B., Brubaker R.R. Passive immunity to Yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immunol 1994, 62(10):4192-4201.
28. Anderson G.W., Worsham P.L., Bolt C.R., Andrews G.P., Welkos S.L., Friedlander A.M., et al. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am J Trop Med 1997, 56(4):471-473.
29. Green M., Rogers D., Russell P., Stagg A.J., Bell D.L., Eley S.M., et al. The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol Med Microb 1999, 23:107-113.
30. Andrews GP, Bolt CR, Pitt LM, Adamovicz JJ. Passive protection in mice from fatal pneumonic plague by antibody raised against a recombinant Yersinia pestis F1-V fusion protein vaccine candidate. American Society for Microbiology Biodefense Research Meeting; March 7-10, 2004.
31. Williamson E.D., Flick-Smith H.C., Waters E., Miller J., Hodgson I., Le Butt C.S., et al. Immunogenicity of the rF1+rV vaccine for plague with identification of the potential immune correlates. Microb Pathog 2007, (42):11-21.
32. Fellows PF, Adamovicz JJ, Norris S, Blackwelder B, Morris S. Protection in mice passively immunized with serum from cynomolgus macaques vaccinated with recombinant plague vaccine (rF1V). American Society for Microbiology Biodefense and Emerging Disease Research Meeting; February 22-25, 2009.
33. National Research Council. Institute of Laboratory Animal Resources. Guide for the Care and Use of Laboratory Animals 1996, National Academies Press, Washington, DC.
34. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maurici M., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004, 289:1-16.
35. Geng D., Shankar G., Schantz A., Rajadhyaksha M., Davis H., Wagner C. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal 2005, 39:364-375.
36. Guyton A.C. Measurement of the respiratory volumes of laboratory animals. Am J Physiol 1947, 150:70-77.
37. Center for Drug Evaluation and Research. Guidance for industry: animal models - essential elements to address efficacy under the animal rule. Food and Drug Administration Department of Health and Human Services, Rockville, MD; 2009 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078923.pdf.
38. Bashaw J., Norris S., Weeks S., Trevino S., Adamovicz J.J., Welkos S. Development of in vitro correlate assays of immunity to infection with Yersinia pestis. Clin Vac Immunol 2007, 14(5):605-616.
39. Zauberman A., Cohen S., Levy Y., Halperin G., Lazar S., Velan B., et al. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague. Vaccine 2008, 26(13):1616-1625.
40. Welkos S., Norris S., Adamovicz J. Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection. Clin Vac Immunol 2008, 15(7):1134-1137.